Spyre Therapeutics Q1 2024 GAAP EPS $(1.20) Misses $(1.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Spyre Therapeutics (NASDAQ:SYRE) reported a Q1 2024 GAAP EPS loss of $(1.20), missing the consensus estimate of $(1.17) by 2.56%.
May 09, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Spyre Therapeutics reported a Q1 2024 GAAP EPS loss of $(1.20), missing the consensus estimate of $(1.17) by 2.56%.
Missing the consensus earnings estimate typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100